Search Results

You are looking at 41 - 50 of 1,139 items for :

Clear All
Full access

Brian Badgwell

multidisciplinary clinical evaluation. This approach is not emphasized in regions of the world where a surgery-first approach is standard of care, radiation therapy is infrequently used, and many cancers are found at an early stage and don't require adjuvant

Full access

Renata R. Urban, Hao He, Rafael Alfonso-Cristancho, Melissa M. Hardesty and Barbara A. Goff

that they treat. In preparation for payment reform, ASCO developed a bundled payment model for the treatment of patients with cancer using chemotherapy. 2 , 3 Ovarian cancer is a complex disease requiring surgery and chemotherapy to achieve the best

Full access

Kimberly L. Johung and Stacey M. Stein

of epirubicin/cisplatin/fluorouracil (ECF) compared with surgery alone, 1 and the Intergroup 0116 trial showed a survival benefit with postoperative chemoradiation (CRT) to 45 Gy and concurrent fluorouracil and leucovorin. 2 More recently, the

Full access

David Scott Miller, Gini Fleming and Marcus E. Randall

; 8 : 423 – 442 . 9 Morrow CP Bundy BN Homesley HD . Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group study

Full access

Jaffer A. Ajani, James S. Barthel, Tanios Bekaii-Saab, David J. Bentrem, Thomas A. D'Amico, Prajnan Das, Crystal Denlinger, Charles S. Fuchs, Hans Gerdes, James A. Hayman, Lisa Hazard, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Lawrence R. Kleinberg, Michael Korn, Kenneth Meredith, Mary F. Mulcahy, Mark B. Orringer, Raymond U. Osarogiagbon, James A. Posey, Aaron R. Sasson, Walter J. Scott, Stephen Shibata, Vivian E. M. Strong, Mary Kay Washington, Christopher Willett, Douglas E. Wood, Cameron D. Wright and Gary Yang

laparoscopic staging differ among various NCCN institutions. In some, laparoscopic staging is reserved for medically fit patients with potentially resectable disease, specifically when chemoradiotherapy or surgery is considered. In medically unfit patients

Full access

Joseph S. Friedberg

Performing surgery for malignant pleural mesothelioma “is like scraping paint off a wall: there is always going to be microscopic disease left,” declared Joseph S. Friedberg, MD, Chief of Thoracic Surgery at Penn Presbyterian Medical Center

Full access

Bing-Yen Wang, Ping-Yi Lin, Shiao-Chi Wu, Hui-Shan Chen, Po-Kuei Hsu, Chih-Shiun Shih, Chao-Yu Liu, Chia-Chuan Liu and Yao-Li Chen

or definitive chemoradiation (only for patients who decline surgery and recommended for cervical esophagus; to view the most recent version of these guidelines, visit NCCN.org ). 3 The largest randomized trials concluded that preoperative

Full access

Saurabh Parasramka, Quan Chen, Bin Huang, Peng Wang and Zin Myint

Background: Non-metastatic muscle invasive bladder cancer (MIBC) is treated with radical cystectomy and survival is closely associated with final pathologic staging. For patients undergoing primary surgery there is evidence that delay > 90 days

Full access

David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis, Leora Horn, Thierry M. Jahan, Mohammad Jahanzeb, Anne Kessinger, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Inga T. Lennes, Billy W. Loo, Renato Martins, Janis O'Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Mary Pinder Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood and Stephen C. Yang

://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2011/Mesothelioma_11protocol.pdf ). 40 Management These guidelines recommend that patients with MPM be managed by a multidisciplinary team with experience in MPM. Treatment options for patients with MPM include surgery, radiotherapy, and

Full access

Vivek Verma

Stereotactic ablative radiotherapy (SABR) is highly controversial compared with surgery for early-stage operable lung cancer. Initial observational data in operable patient cohorts showed that outcomes for SABR were roughly equal to those of